Kymera Therapeutics, Inc. (NASDAQ: KYMR)

$82.30 ▼ -1.80 (-2.14%)

As of May 12, 2026 12:06 PM

Sector: Healthcare Industry: Biotechnology CIK: 0001815442

Market Cap 6.88 Bn

P/E -22.07

P/S 175.45

Div. Yield 0.00

Revenue Growth (1y) (Qtr) 55.50

Add ratio to table...

About

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops oral small molecule medicines using its targeted protein degradation platform to treat immune inflammatory diseases. The company was founded to pursue a drug discovery approach that targets disease causing proteins previously considered undruggable by conventional small molecules. Its pipeline includes programs focused on STAT6, IRF5, IRAK4, and CDK2, each aimed at delivering oral therapies with potential biologics like efficacy. Kymera aims to advance at least...

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops oral small molecule medicines using its targeted protein degradation platform to treat immune inflammatory diseases. The company was founded to pursue a drug discovery approach that targets disease causing proteins previously considered undruggable by conventional small molecules. Its pipeline includes programs focused on STAT6, IRF5, IRAK4, and CDK2, each aimed at delivering oral therapies with potential biologics like efficacy. Kymera aims to advance at least one new molecular entity into clinical testing each year while building integrated capabilities for future commercialization. The company’s mission is to reinvent treatment of human disease by creating medicines that eliminate disease causing proteins rather than merely inhibiting their function. By harnessing the cell’s natural ubiquitin proteasome system, Kymera aims to achieve deeper and more durable target suppression. The company continues to invest in its discovery engine to identify additional high value targets that are amenable to its technology.

The company currently generates revenue through upfront payments, milestone payments, and royalties from collaboration agreements with pharmaceutical partners such as Sanofi and Gilead Sciences. As a pre revenue entity, Kymera has not yet recorded product sales and relies on these partnership financings to support research and development. Payments received include an upfront fee of one hundred fifty million dollars from the Sanofi collaboration and a forty million dollar upfront fee from the Gilead agreement. Additional potential earnings consist of development milestones, commercial milestones, and tiered royalties on future net sales. Milestone payments are triggered by predefined development, regulatory, or commercial achievements under the collaboration agreements. Royalty rates are structured as tiered percentages of net sales, offering upside potential if the partnered drugs reach the market. These financial arrangements allow Kymera to advance its programs while preserving capital for future internal initiatives.

Kymera Therapeutics is considered a leader in the targeted protein degradation field, competing with firms such as Arvinas, C4 Therapeutics, Nurix Therapeutics, and Foghorn Therapeutics. The company differentiates itself through a proprietary platform that enables degradation of transcription factors and other scaffolding proteins that are difficult to drug with traditional approaches. Its extensive patent estate covers E3 ligase ligand technologies and a range of degrader molecules, providing long term protection for its innovations. Kymera focuses on oral delivery of biologics like activity, seeking to improve patient convenience and broaden access compared to injectable alternatives. The firm’s scientific expertise in E3 ligase biology enables it to design molecules that are both potent and highly selective. This selectivity aims to reduce off target effects and improve safety profiles compared with less precise modalities. Its collaborative model with established pharmaceutical partners provides validation and access to broader development resources.

The company’s intended customers are patients suffering from immune inflammatory conditions such as atopic dermatitis, asthma, lupus, and rheumatoid arthritis, as well as the healthcare providers and payors that serve them. These conditions affect millions of people in the United States, Europe, and Japan, representing a significant unmet need for effective oral therapies. Kymera’s current collaborations involve Sanofi and Gilead Sciences, which fund and develop specific drug candidates targeting IRAK4 and CDK2 respectively. Successful commercialization would lead to distribution through pharmacies and healthcare providers, with payors assessing coverage and reimbursement for the new oral medicines. In addition to immune inflammatory diseases, Kymera explores oncology targets such as CDK2 through its collaboration with Gilead. The breadth of its pipeline reflects a strategy to apply the degradation platform across multiple therapeutic areas where high unmet need exists. By focusing on oral administration, Kymera seeks to address patient preferences for convenient dosing regimens.

Investment thesis

Bull case

Kymera’s flagship STAT6 degrader, KT‑621, offers biologics‑like efficacy in a once‑daily oral pill, addressing a vast unmet need across atopic dermatitis, asthma, COPD, and other type‑2 diseases that collectively affect more than 130 million people worldwide. The current injectable biologics for these conditions have low penetration rates; an oral alternative could unlock a significant portion of this patient population while providing convenience and potentially higher adherence. The company has demonstrated robust STAT6 degradation at low doses in healthy volunteers, indicating high potency and the likelihood of achieving clinical efficacy comparable to the approved biologic dupilumab. A global, randomized, double‑blind, placebo‑controlled Phase IIb trial (BROADEN2) with 200 patients is already underway, and the expected top‑line data in mid‑2027 will provide the regulatory evidence needed for Phase III filing. The catalytic degrader platform may also lower development costs relative to biologics, further enhancing commercial appeal.
Kymera’s pipeline is not limited to STAT6; the IRF5 degrader, KT‑579, targets lupus, rheumatoid arthritis, inflammatory bowel disease, and other interferon‑related disorders, a disease space with few oral options. Preclinical data show superior efficacy over existing small‑molecule inhibitors and biologics, suggesting the potential to launch multiple indications with a single platform. IND‑enabling studies for KT‑579 were completed in 2024, positioning a Phase I healthy‑volunteer study for early 2026 and a multi‑year commercialization trajectory. This depth of pipeline diversifies risk and provides investors with long‑term upside beyond the single asset.
The partnership with Gilead for a CDK2 oncology glue program provides both financial support and external validation of Kymera’s degraders platform. The upfront payment and milestone potential ($85 million total, half already received) strengthen the company’s cash runway, enabling the STAT6 program to advance toward Phase III without immediate capital constraints. Gilead’s oncology expertise could accelerate preclinical and clinical translation of the CDK2 program, creating a future growth catalyst that is not yet fully reflected in the market price.
Kymera’s cash balance of $978.7 million at the end of Q3 2025 provides a runway extending well beyond 2028, far exceeding typical biotech lifecycles for a first‑in‑class program. This robust liquidity mitigates the risk of funding shortfalls that could delay trials or limit data generation. The company’s disciplined expense management—reducing R&D spend by 7 % year‑over‑year—demonstrates operational efficiency that investors can rely on. The cash cushion also allows Kymera to absorb regulatory setbacks or trial failures without immediate external financing, preserving their strategic trajectory.
Kymera’s focus on catalytic protein degradation, rather than receptor blockade, promises superior pharmacodynamic profiles with 24/7 pathway suppression. Early data indicating durable biomarker suppression in healthy volunteers (TARC, Eotaxin‑3) even after dosing cessation supports the claim of sustained pharmacology. This could translate into better clinical outcomes, fewer dosing frequency demands, and improved patient adherence relative to biologics. The unique mechanism may also lower the risk of developing anti‑drug antibodies, a significant concern with monoclonal antibodies.

Kymera’s flagship STAT6 degrader, KT‑621, offers biologics‑like efficacy in a once‑daily oral pill, addressing a vast unmet need across atopic dermatitis, asthma, COPD, and other type‑2 diseases that collectively affect more than 130 million people worldwide. The current injectable biologics for these conditions have low penetration rates; an oral alternative could unlock a significant portion of this patient population while providing convenience and potentially higher adherence. The company has demonstrated robust STAT6 degradation at low doses in healthy volunteers, indicating high potency and the likelihood of achieving clinical efficacy comparable to the approved biologic dupilumab. A global, randomized, double‑blind, placebo‑controlled Phase IIb trial (BROADEN2) with 200 patients is already underway, and the expected top‑line data in mid‑2027 will provide the regulatory evidence needed for Phase III filing. The catalytic degrader platform may also lower development costs relative to biologics, further enhancing commercial appeal.
Kymera’s pipeline is not limited to STAT6; the IRF5 degrader, KT‑579, targets lupus, rheumatoid arthritis, inflammatory bowel disease, and other interferon‑related disorders, a disease space with few oral options. Preclinical data show superior efficacy over existing small‑molecule inhibitors and biologics, suggesting the potential to launch multiple indications with a single platform. IND‑enabling studies for KT‑579 were completed in 2024, positioning a Phase I healthy‑volunteer study for early 2026 and a multi‑year commercialization trajectory. This depth of pipeline diversifies risk and provides investors with long‑term upside beyond the single asset.
The partnership with Gilead for a CDK2 oncology glue program provides both financial support and external validation of Kymera’s degraders platform. The upfront payment and milestone potential ($85 million total, half already received) strengthen the company’s cash runway, enabling the STAT6 program to advance toward Phase III without immediate capital constraints. Gilead’s oncology expertise could accelerate preclinical and clinical translation of the CDK2 program, creating a future growth catalyst that is not yet fully reflected in the market price.
Kymera’s cash balance of $978.7 million at the end of Q3 2025 provides a runway extending well beyond 2028, far exceeding typical biotech lifecycles for a first‑in‑class program. This robust liquidity mitigates the risk of funding shortfalls that could delay trials or limit data generation. The company’s disciplined expense management—reducing R&D spend by 7 % year‑over‑year—demonstrates operational efficiency that investors can rely on. The cash cushion also allows Kymera to absorb regulatory setbacks or trial failures without immediate external financing, preserving their strategic trajectory.
Kymera’s focus on catalytic protein degradation, rather than receptor blockade, promises superior pharmacodynamic profiles with 24/7 pathway suppression. Early data indicating durable biomarker suppression in healthy volunteers (TARC, Eotaxin‑3) even after dosing cessation supports the claim of sustained pharmacology. This could translate into better clinical outcomes, fewer dosing frequency demands, and improved patient adherence relative to biologics. The unique mechanism may also lower the risk of developing anti‑drug antibodies, a significant concern with monoclonal antibodies.

Bear case

Despite encouraging early data, the clinical efficacy of KT‑621 remains unproven in a full Phase IIb setting, and the company has not yet demonstrated statistically significant benefit over placebo in the primary endpoint. The company’s own statements emphasize uncertainty around the magnitude of clinical effect, with the CEO and CRO explicitly refusing to provide precise efficacy estimates until December. This lack of concrete data raises significant doubts about whether the drug will reach regulatory approval or generate commercial traction.
The Phase Ib study’s design—a 28‑day, biomarker‑focused, non‑placebo controlled portion—provides limited insight into the drug’s true therapeutic impact. While biomarker reductions are encouraging, the absence of a placebo arm for clinical endpoints leaves open the possibility that observed improvements could be due to placebo or natural disease fluctuation. The company’s emphasis on biomarkers may obscure clinical relevance, leading to potential over‑optimism about efficacy.
The company’s high R&D spend ($74.1 million in Q3 2025, with 8.4 million in non‑cash stock compensation) combined with a modest revenue ($2.8 million) indicates a large burn relative to cash reserves. Although the cash runway extends to 2028, the company still faces a heavy funding requirement as it progresses toward Phase III and commercialization. Any delays in trial results or regulatory setbacks could deplete reserves faster than projected, forcing a capital raise at an uncertain valuation.
Kymera’s reliance on partnership milestones (e.g., Gilead and Sanofi) introduces external timing risk. Milestone payments are contingent on partner actions and can be delayed or reduced, which would affect cash flows. The partnership with Gilead’s CDK2 program, while potentially lucrative, is outside Kymera’s core immunology focus and could dilute focus or shift resources away from the STAT6 program, jeopardizing its timeline.
The oral degrader platform, while innovative, has limited historical precedent for clinical success. The only comparable therapeutic classes are biologics and small‑molecule inhibitors, each with distinct safety profiles and market dynamics. Regulatory agencies may scrutinize the new mechanism more heavily, potentially leading to extended review times or the requirement for additional data, which would delay market entry and inflate costs.

Despite encouraging early data, the clinical efficacy of KT‑621 remains unproven in a full Phase IIb setting, and the company has not yet demonstrated statistically significant benefit over placebo in the primary endpoint. The company’s own statements emphasize uncertainty around the magnitude of clinical effect, with the CEO and CRO explicitly refusing to provide precise efficacy estimates until December. This lack of concrete data raises significant doubts about whether the drug will reach regulatory approval or generate commercial traction.
The Phase Ib study’s design—a 28‑day, biomarker‑focused, non‑placebo controlled portion—provides limited insight into the drug’s true therapeutic impact. While biomarker reductions are encouraging, the absence of a placebo arm for clinical endpoints leaves open the possibility that observed improvements could be due to placebo or natural disease fluctuation. The company’s emphasis on biomarkers may obscure clinical relevance, leading to potential over‑optimism about efficacy.
The company’s high R&D spend ($74.1 million in Q3 2025, with 8.4 million in non‑cash stock compensation) combined with a modest revenue ($2.8 million) indicates a large burn relative to cash reserves. Although the cash runway extends to 2028, the company still faces a heavy funding requirement as it progresses toward Phase III and commercialization. Any delays in trial results or regulatory setbacks could deplete reserves faster than projected, forcing a capital raise at an uncertain valuation.
Kymera’s reliance on partnership milestones (e.g., Gilead and Sanofi) introduces external timing risk. Milestone payments are contingent on partner actions and can be delayed or reduced, which would affect cash flows. The partnership with Gilead’s CDK2 program, while potentially lucrative, is outside Kymera’s core immunology focus and could dilute focus or shift resources away from the STAT6 program, jeopardizing its timeline.
The oral degrader platform, while innovative, has limited historical precedent for clinical success. The only comparable therapeutic classes are biologics and small‑molecule inhibitors, each with distinct safety profiles and market dynamics. Regulatory agencies may scrutinize the new mechanism more heavily, potentially leading to extended review times or the requirement for additional data, which would delay market entry and inflate costs.

Award Date Breakdown of Revenue (2025)

Plan Name Breakdown of Revenue (2025)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	109.62 Bn	27.71	9.13	-
2	REGN	Regeneron Pharmaceuticals, Inc.	73.93 Bn	16.38	5.15	1.99 Bn
3	ALNY	Alnylam Pharmaceuticals, Inc.	40.50 Bn	147.21	12.86	-
4	RVMD	Revolution Medicines, Inc.	27.39 Bn	-24.25	33,000.01	-
5	ZLAB	Zai Lab Ltd	23.74 Bn	-135.44	97.90	0.20 Bn
6	MESO	Mesoblast Ltd	23.66 Bn	-185.34	1,375.67	0.12 Bn
7	RPRX	Royalty Pharma plc	21.54 Bn	27.99	9.06	8.95 Bn
8	ROIV	Roivant Sciences Ltd.	19.92 Bn	-32.48	3,470.34	-

Research Tools